GSK4347859 vs PBO, Ph1, HV, SD&RD DE, FTIH, Safety, PK/PD

• Research type

  Research Study

• Full title

  A Phase 1, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of GSK3996401 following single and multiple ascending doses of GSK4347859 in healthy participants.

• IRAS ID

  1008764

• Contact name

  Farazana Habib-Ullah

• Contact email

  farazana.x.habib-ullah@gsk.com

• Sponsor organisation

  GlaxoSmithKline Research & Development Limited

• Clinicaltrials.gov Identifier

  NCT06188507

• Research summary

  https://clinicaltrials.gov/study/NCT06188507
  

• REC name

  East of England - Cambridge East Research Ethics Committee

• REC reference

  23/EE/0259

• Date of REC Opinion

  12 Dec 2023

• REC opinion

  Further Information Favourable Opinion